WO2006005017A3 - Oral composition comprising carbamylating agent - Google Patents

Oral composition comprising carbamylating agent Download PDF

Info

Publication number
WO2006005017A3
WO2006005017A3 PCT/US2005/023624 US2005023624W WO2006005017A3 WO 2006005017 A3 WO2006005017 A3 WO 2006005017A3 US 2005023624 W US2005023624 W US 2005023624W WO 2006005017 A3 WO2006005017 A3 WO 2006005017A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral composition
carbamylating agent
agent
carbamylating
diluent
Prior art date
Application number
PCT/US2005/023624
Other languages
French (fr)
Other versions
WO2006005017A2 (en
Inventor
Jekone Zsuzsanna Bentzil
Sabine Gutman
Original Assignee
Valeant Res & Dev
Jekone Zsuzsanna Bentzil
Sabine Gutman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Res & Dev, Jekone Zsuzsanna Bentzil, Sabine Gutman filed Critical Valeant Res & Dev
Publication of WO2006005017A2 publication Critical patent/WO2006005017A2/en
Publication of WO2006005017A3 publication Critical patent/WO2006005017A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to fast release oral compositions containing a carbamylating agent, such as pyridostigmine bromide, a hydrophobic agent and a diluent, and methods of administering and preparing such compositions.
PCT/US2005/023624 2004-06-30 2005-06-30 Oral composition comprising carbamylating agent WO2006005017A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58434904P 2004-06-30 2004-06-30
US60/584,349 2004-06-30

Publications (2)

Publication Number Publication Date
WO2006005017A2 WO2006005017A2 (en) 2006-01-12
WO2006005017A3 true WO2006005017A3 (en) 2006-04-20

Family

ID=35783388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023624 WO2006005017A2 (en) 2004-06-30 2005-06-30 Oral composition comprising carbamylating agent

Country Status (2)

Country Link
TW (1) TW200706173A (en)
WO (1) WO2006005017A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356984A1 (en) * 2010-02-04 2011-08-17 Nycomed Austria GmbH Improved distigmine bromide formulation
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
TW201919704A (en) 2017-07-25 2019-06-01 美商Ｇｔ生物製藥公司 Pharmaceutical compositions and methods utilizing PYRIDOSTIGMINE and a NK-1 antagonist for treating myasthenia gravis
WO2019023175A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. Pharmaceutical compositions and methods utilizing neostigmine and a nk-1 antagonist for treating myasthenia gravis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
US FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH, 5 February 2003 (2003-02-05), Retrieved from the Internet <URL:http://www.fda.gov/cder/drg/infopage/Pyridostigmine_Bromide/Q&A.htm> *

Also Published As

Publication number Publication date
TW200706173A (en) 2007-02-16
WO2006005017A2 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2006114520A3 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2006031878A3 (en) Imidazoquinoline compounds
WO2007090393A3 (en) Microtablet-based pharmaceutical preparation
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2007079139A3 (en) Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2002056861A3 (en) Syntactic deformable foam compositions and methods for making
WO2006024479A3 (en) Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin
WO2008013840A3 (en) Erastin analogs and uses thereof
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2006056695A8 (en) Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof
WO2007122581A3 (en) Compositions and kits of phenylephrine
WO2007062370A3 (en) Calcilytic compounds
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
MX2008001560A (en) Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds.
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
EP1797078A4 (en) Compounds, compositions containing them, preparation thereof and uses thereof iii

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase